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Abstract
Introduction: Alpha-1-antitrypsin deficiency (AATD), genetic risk factor for premature chronic obstructive pulmonary disease (COPD), often remains 
undetected. The aim of our study was to analyse the effectiveness of an integrative laboratory algorithm for AATD detection in patients diagnosed 
with COPD by the age of 45 years, in comparison with the screening approach based on AAT concentration measurement alone.
Subjects and methods: 50 unrelated patients (28 males / 22 females, age 52 (24-75 years) diagnosed with COPD before the age of 45 years were 
enrolled. Immunonephelometric assay for alpha-1-antitrypsin (AAT) and PCR-reverse hybridization for Z and S allele were first-line, and isoelectric 
focusing and DNA sequencing (ABI Prism BigDye) were reflex tests.
Results: AATD associated genotypes were detected in 7 patients (5 ZZ, 1 ZMmalton, 1 ZQ0amersfoort), 10 were heterozygous carriers (8 MZ and 2 MS ge-
notypes) and 33 were without AATD (MM genotype). Carriers and patients without AATD had comparable AAT concentrations (P = 0.125). In majority 
of participants (48) first line tests were sufficient to analyze AATD presence. In two remaining cases reflex tests identified rare alleles, Mmalton and 
Q0amersfoort, the later one being reported for the first time in Serbian population. Detection rate did not differ between algorithm and screening both 
for AATD (P = 0.500) and carriers (P = 0.063).
Conclusion: There is a high prevalence of AATD affected subjects and carriers in a group of patients with premature COPD. The use of integrative 
laboratory algorithm does not improve the effectiveness of AATD detection in comparison with the screening based on AAT concentration alone.
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Introduction
Chronic obstructive pulmonary disease (COPD) is 
highly prevalent global cause of mortality and 
morbidity (1). Up to 5% of patients are genetically 
predisposed to premature COPD due to the alpha-
1-antitrypsin deficiency (AATD) (2). This condition 
develops as the consequence of homozygosity or 
compound heterozygosity for the deficiency alle-
les of SERPINA1, gene encoding for alpha-1-antit-
rypsin (AAT). In contrast to the functional (M) alle-
les, these variants are associated with the reduced 
AAT concentration and functionality. Regarding 
prevalence, deficiency alleles are classified as com-
mon (Z, S) or rare (Mmalton, Siiyama, Mheerlen, Mprocida, 
null alleles etc) (3). Timely detection of AATD al-
lows significant health benefits like AAT augmen-
tation and genetic counselling. Nevertheless, it is 
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estimated that only a minority (4-5%) of COPD pa-
tients with AATD are identified (2).
World Health Organization (WHO) and different 
pulmonologists’ associations advise measurement 
of AAT concentration as screening in COPD gener-
ally, with the special emphasis on targeted groups 
(i.e. those diagnosed with COPD before the age of 
45, patients with family history of COPD). In case of 
decreased concentration, it is recommended to 
analyse patient’s pheno- or genotype (3).
Laboratory methods for testing AATD are associ-
ated with different limitations. Immunonephelom-
etric assays provide data about AAT serum con-
centration, whereby different acquired factors (in-
flammation, hepatic or renal failure) significantly 
limit their reliability. In phenotyping, difficulties in 
interpretation and technical performance of thin-
layer isoelectric focusing (IEF) can be encountered. 
For molecular techniques caution is necessary 
since rare alleles might not be detected unless 
standard genotyping is followed by sequencing. 
To overcome these issues and improve effective-
ness of AATD testing, several centers have inte-
grated methods and created laboratory algorithms 
for AATD detection (4-6). Following their experi-
ence, integrative algorithm was proposed with in-
tention to increase AATD detection among Serbian 
patients. Algorithm starts with concomitant deter-
mination of AAT concentration and genotyping for 
Z and S alleles. IEF is performed as the reflex test 
to resolve discrepancies between the AAT concen-
tration and associated genotype-concentration 
bellow 0.90 g/L and MM, 0.61 g/L and MZ or 0.84 
g/L and MS genotype. Additional or bands with al-
tered position in gel pattern indicate the presence 
of rare alleles, which has to be confirmed with DNA 
sequencing. If no specific bands are observed, the 
most probable cause of discrepancy could be at-
tributed to acquired conditions affecting AAT con-
centration. Nevertheless, caution is needed in such 
situations to avoid neglecting of null allele pres-
ence and referring sample to DNA sequencing (7).
Considering the limited reliability of AAT concen-
tration due to the effects of acquired factors, we 
hypothesized that an integrative algorithm could 
lead to the improved effectiveness by assuring 
AATD detection in heterozygous carriers with AAT 
concentration in reference range. The aim of our 
study was to analyse the effectiveness of an inte-
grative laboratory algorithm for AATD detection in 
patients diagnosed with COPD by the age of 45 
years, in comparison with the screening approach 
based on AAT concentration measurement alone.
Materials and methods
Study design
This cross-sectional study included patients from 
the Clinic for Lung Diseases in Clinical Center of 
Serbia, Belgrade. They were recruited from Janu-
ary 2011 till December 2013. Laboratory testing 
was performed in the Center for Medical Biochem-
istry in Clinical Center of Serbia and Institute of 
Molecular Genetics and Genetic Engineering, Uni-
versity of Belgrade. The study was approved by 
the Ethics Committee of Clinical Center of Serbia 
and all patients signed written consent.
Patients
The study enrolled fifty unrelated COPD patients 
(28 males and 22 females, 52 (24-75) years). Includ-
ed were patients with the age ≤ 45 years at the 
time of COPD diagnosis in whom AATD presence 
was not investigated prior to inclusion in the study. 
COPD was diagnosed on the basis of spirometry 
measurements: ratio of postbronchodilator forced 
expiratory volume in 1 s (FEV1) to forced vital ca-
pacity (FVC) less than 0.7 and FEV1 less than 80% 
(8).
Blood sampling
Venepunction was performed in the sitting posi-
tion at 8 a.m., after the overnight fasting (9). Blood 
was collected in two Vacutainer® (BD Vacutainer, 
Franklin Lakes, NJ, USA) tubes - one SST® II Advance 
and one with 0.105 mol/L sodium citrate. Serum 
was separated after centrifugation for 15 minutes 
at 1500 x g and stored at -20 °С for up to 4 weeks. 
DNA was isolated with Illustra blood genomic Prep 
Mini Spin Kit® (GE Healthcare, Little Chalfont, UK), 
following manufacturer’s instructions, and kept at 
+4 °С.
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Laboratory methods
AAT concentration was measured with immunon-
ephelometry assay using N Antiserum to human 
α1-Antitrypsin (Siemens Healthcare Diagnostics 
Products GmbH, Marburg, Germany) on BN II® 
Nephelometer (same manufacturer). According to 
the manufacturer’s data, method reference range 
is 0.90-2.00 g/L, and within-run and between-run 
coefficients of variation were 1.8% and 1.2% at 1.46 
g/L and 2.3% and 1.1% at 2.03 g/L respectively.
IEF was performed on precasted polyacrylamide 
gels plates (245 x 110 x 1 mm, Т = 5% & С = 3%, рН 
gradient = 4.0–5.0), under the conditions recom-
mended by the manufacturer (GE Healthcare, Lit-
tle Chalfont, UK). Phenotype was analyzed through 
gel patterns comparison with commercial samples 
of known phenotype (Sebia, Evry Cedex, France).
Genotyping for Z and S allele was performed us-
ing the PCR-reverse ASO hybridization GenoType® 
ААТ kit (Hain Lifescience GmbH, Nehren, Germa-
ny), according to the manufacturer’s instructions. 
PCR-direct sequencing was performed with the 
following primers: 5’-TGTCAATCCCTGATCACT-3’/5’-
TTGCTTGTTTCTATGGGAAC-3’; 5’-GGTTTCTTTAT-
TCTGCTACA-3’/5’-TCAGTCCCAACATGGCTAA-3’; 5’- 
GGCAGAAATAATCAGAAAAG -3’/5’- TGGTATCTG-
TAGGGAAGA -3’; and 5’- GTGACAGGGAGGGAGAG-
GA -3’/5’-GGAGGGATTTACAGTCACAT-3’ (Eurofins 
MWG Operon, Huntsville, AL, USA) for SERPINA1 
exons 2, 3, 4 and 5. ABI Prism BigDye Terminator 
Kit v3.1 Cycle Sequencing Kit and Sequencing 
Analysis Software v5.2 Patch were employed ac-
cording to manufacturer’s instructions (Applied 
Biosystems, Life Technologies, Thermo Fisher Sci-
entific brand of Waltham, Massachusetts, USA).
Statistical analysis
Absolute frequencies were presented for geno-
types and ratios for allelic frequencies. AAT con-
centration was presented as median with range 
(min-max). Kruskal-Wallis and Mann-Whitney U 
test with Boniferroni correction were used to com-
pare AAT concentrations between groups of pa-
tients with different AATD status. Differences in 
number of detected AATD cases and carriers were 
tested using McNemar Chi-square test for depend-
ent samples with exact P module. Data analysis 
was performed with statistical software SPSS® ver-
sion 22.0 (IBM®, New York, USA, trial version). P value 
bellow 0.05 was considered statistically significant.
Results
Data about detected genotypes and correspond-
ing AAT concentrations are presented in Table 1. 
Calculated allelic frequencies were 0.2, 0.02 and 
0.76 for Z, S and M allele respectively, while joint 
frequency of rare alleles was 0.02. AATD was de-
tected in 7 and carrier state in 10 cases. AAT con-
centration in patients with AATD (0.20 (0.11-0.26) 
g/L) was significantly lower in comparison both 
with AATD carriers (0.96 (0.65-2.30) g/L; P < 0.001) 
and patients without AATD (1.31 (0.92-2.35) g/L; P 
< 0.001). In addition, no significant difference was 
observed between last two groups (P = 0.125), 
whereby the half of carriers (3 with MZ and 2 with 
MS genotype) had AAT concentration in the refer-
ence range.
Table 1. Detected genotypes and corresponding AAT concen-
trations.
Genotype Number of patients
AAT concentration 
(g/L)
ZZ 5 0.21 (0.20-0.26)
Rare 
(ZMmalton, ZQ0amersfoort)
2 0.16 (0.11-0.20)
MZ 8 0.77 (0.65-2.27)
MS 2 1.72 (1.14-2.30)
MM 33 1.36 (0.92-2.35)
The results obtained in the first diagnostic line 
were sufficient to evaluate the presence of AATD 
in 48 of enrolled patients. Discrepancy between 
immunonephelometry and results of genotyping 
for Z allele, was encountered in two cases.
Case 1: AAT concentration of 0.20 g/L was matched 
with MZ genotype. IEF pattern (Figure 1A) showed 
additional band positioned slightly cathodal com-
pared with bands corresponding to M2 allele, thus 
indicative for Mmalton. The presumption was con-
firmed by sequencing (Figure 1B), leading to the 
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conclusion that the patient was heterozygote for Z 
and Mmalton alleles.
Case 2: AAT concentration of 0.11 g/L was meas-
ured and MZ genotype detected. IEF gel pattern 
contained no additional bands. The presence of 
null allele was suspected and confirmed by se-
quencing, which identified Q0amersfoort (Figure 2).
The difference in effectiveness of the screening 
approach in this group was estimated from the 
obtained results. Five carriers remained undetec-
ted and two AATD (compound heterozygotes for 
Z and rare alleles) could not be unequivocally de-
termined. Nevertheless, the estimated effective-
ness was not significantly different from integra-
tive algorithm both for AATD (P = 0.500) and carri-
ers (P = 0.063).
Discussion
Our study showed that integrative algorithm re-
vealed rather high prevalence of AATD in a group 
of patients with premature COPD. Majority of af-
fected subjects inherited Z allele homozygously, 
Figure 1. Identification of Mmalton allele.
1A - Determination of AAT phenotype in the patient and comparison to controls of the MM, MZ, and ZZ phenotype.
1B - DNA sequence of part of exon 2 in the SERPINA1, showing the heterozygous form of in- frame deletion of TTC codon for Phe75 or 
Phe76.
Figure 2. Identification of Q0amersfoort allele.
DNA sequence of part of exon 2 in the SERPINA1, showing the heterozygous form of Tyr184TAC – stop184TAG.
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while compound heterozygosity with rare alleles 
was detected in two patients. In the half of the 
heterozygous carriers AAT concentration was in 
the reference range, indicating that they would be 
undetected by screening relying only on AAT con-
centration. Nevertheless the integrative algorithm 
was not shown to be more effective than screen-
ing based on AAT concentration alone, in the in-
vestigated group.
Previously reported AATD percentage in unselect-
ed COPD patients, ranging from 0.5 to 10.4 (10), 
was much lower than the prevalence obtained in 
this study. Additionally, in a group of randomly col-
lected Serbian COPD patients AATD prevalence 
was found to be 2.9% (11) There is only one report 
on AATD prevalence among targeted COPD pa-
tients (premature emphysema, emphysema with 
no recognized risk factor, pneumothorax) which 
exceeded 40% (12). Taken together with the last 
example, our results might suggest that targeting 
on patients with premature COPD might be a use-
ful mode to increase AATD detection rate. Never-
theless, this presumption has to be confirmed in a 
larger cohort of patients.
Previously reported overlapping between AAT 
concentrations corresponding to AATD carriers 
and patients with no AATD (3,6,13) was evidenced 
in the investigated patients. Through concomitant 
measurement of serum AAT concentration and 
genotyping for Z and S allele, integrative algo-
rithm diminished the possibility that carriers re-
main undetected. It is noteworthy that this combi-
nation also improves diagnostic accuracy because 
genotyping for Z and S allele, if performed alone, 
might miss rare alleles (5,6,14). Regarding the in-
vestigated group, two patients might be errone-
ously classified as carriers of Z allele.
The reliable detection of rare alleles is very impor-
tant criterion for algorithm application (15). Their 
presence was confirmed in two patients, one car-
rying ZMmalton genotype and the other ZQ0amers-
foort. Mmalton is derived from the functional allele by 
the deletion of a TTC codon. Consequential lack of 
a phenylalanine residue potentiates protein aggre-
gation in hepatocytes, while serum concentrations 
reach less than 15% of normal. The presence of this 
allele is associated with lung and liver disease (16). 
According to the currently available data, the in-
dex case with MmaltonZ genotype from this study is 
the second reported in Serbian population (17). 
Q0amersfoort is characterized by the nonsense muta-
tion leading to the formation of TAG stop codon. 
Reliable data about clinical significance of this al-
lele are not yet available (18). The index case with 
Q0amersfoort Z genotype identified in this study is 
the first report about this allele in patients of Ser-
bian origin.
Rather small and preselected group of patients, re-
cruited in a single institution is the main limitation 
of the study. In addition, the presence of addition-
al COPD risk factors (smoking, air pollution expo-
sure) was not considered during the recruitment. 
For these reasons the observed positive outcomes 
should be regarded as “pilot”. Moreover, they 
might explain why the integrative algorithm was 
not shown to be more effective than previously 
recommended screening approach based on AAT 
measurement. To resolve this issues further stud-
ies in larger cohorts of COPD patients, both unse-
lected and targeted are recommended.
Conclusion
There is a high prevalence of AATD affected sub-
jects and carriers in patients with premature COPD. 
The use of integrative laboratory algorithm does 
not improve the effectiveness of AATD detection 
in comparison with the screening based on AAT 
concentration alone.
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